Bavarian Nordic has entered into an agreement to sell its Priority Review Voucher (PRV) for a total of USD 160 million. The Company was awarded the PRV in February 2025 following the FDA approval of the chikungunya vaccine VIMUNYA. National Institutes of Health (NIH) will receive 20 percent of the gross proceeds under the license agreement. The revenue is reported as other operating income and does not impact the 2025 revenue forecast, but the EBITDA margin is expected to be positively impacted. The transaction is expected to close in the third quarter of 2025.
Bavarian Nordic sells Priority Review Voucher for 160 MUSD
Notes
Mentice consolidates operations to Denver
Bio-Works secures million-dollar order from global pharmaceutical company
OncoZenge receives investment proceeds from Yangtian Bio-Pharmaceutical
Xspray Pharma confirms bioequivalence for XS003
Evaxion converts debt of EUR 3,5 million
NEWSLETTER
NEWS
AI-designed proteins are created in seconds
The price of Leqembi needs to be lowered in Japan
Merck gears up in lung diseases with giant acquisition
Upcoming events!
Investing in Life Science
Discover unparalleled opportunities, set in the vibrant heart of Stockholm. This premier event unites forward-thinking investors and business leaders to...
Life Science Summit
The Nordic region's leading forum for early-stage and growth-phase life science companies. The Summit bridges innovation and capital by providing...
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account
Chronicles
The market is taking Trump's tariff threat in stride
The EU's new life science strategy – a step in the right direction or just fluff?
